This is the authors' abstract. We don't add key points for this paper.
The urokinase plasminogen activator (uPA) is a widely studied anticancer drug target with multiple classes of inhibitors reported to date. Many of these inhibitors contain amidine or guanidine groups, while others lacking these groups show improved oral bioavailability. Most of the X-ray co-crystal structures of small molecule uPA inhibitors show a key salt bridge with the side chain carboxylate of Asp189 in the S1 pocket of uPA. This review summarises the different classes of uPA inhibitors, their binding interactions and experimentally measured inhibitory potencies and highlights species selectivity issues with attention to recently described 6-substituted amiloride and 5‐N,N-(hexamethylene)amiloride (HMA) derivatives.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Salamouni et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: